Kohn CG, et al. - Researchers used US MarketScan claims from January 2012-December 2016 to evaluate the link between rivaroxaban and warfarin and risk of major bleeding in unprovoked venous thromboembolism (VTE) patients. Patients who had ≥1 primary hospitalization/emergency department visit diagnosis code for an unprovoked VTE, were newly-initiated on rivaroxaban or warfarin within 30-days after the VTE and, had ≥12-months of insurance coverage prior to the VTE were included in this study. In unprovoked VTE, reduced risk of overall, gastrointestinal and intracranial major bleeding was observed in association with rivaroxaban vs warfarin treatment. In rivaroxaban patients, no bleeding subtype was seen significantly more frequently.